




Betrixaban

Revised: July 15, 2023.

CASRN: 330942-05-7



Drug Levels and Effects

Summary of Use during Lactation

Betrixaban is no longer marketed in the United States. Because no information is available on the use of betrixaban during breastfeeding and the drug is orally absorbable, an alternate drug is preferred, especially while nursing a newborn or preterm infant.[1,2]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Acenocoumarol, Dalteparin, Enoxaparin, Heparin, Rivaroxaban, Warfarin

References

1. Vanassche T, Vandenbriele C, Peerlinck K, et al. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. *Expert Opin Pharmacother*. 2015;16:645–58. PubMed PMID: 25554350.
2. Cohen H, Arachchillage DR, Beyer-Westendorf J, et al. Direct oral anticoagulants and women. *Semin Thromb Hemost*. 2016;42:789–97. PubMed PMID: 27706531.

Substance Identification

Substance Name

Betrixaban

CAS Registry Number

330942-05-7

Drug Class

Breast Feeding

Lactation

Milk, Human

Anticoagulants

Antithrombins